News Author: Sharon Worcester Publish date: June 29, 2017
Temporary treatment breaks are acceptable in some breast cancer patients.
News Author: Sharon Worcester Publish date: June 26, 2017
CHICAGO – HR– tumors may derive more benefit from dual HER2 blockade.
News Author: Sharon Worcester Publish date: June 21, 2017
A Food and Drug Administration advisory committee voted 17-2 in support of a supplemental new drug application for liraglutide (Victoza) injections...
News Author: Sharon Worcester Publish date: June 16, 2017
CHICAGO – Nine weeks of treatment with trastuzumab resulted in comparable disease-free and overall survival to that seen with the standard 12 month...
News Author: Sharon Worcester Publish date: June 15, 2017
Women with stage III endometrial cancer in the combined CT/RT arm experienced a statistically significant 11% improvement in FFS – defined as relap...
News Author: Sharon Worcester Publish date: June 15, 2017
CHICAGO – Secondary cytoreductive surgery resulted in a clinically meaningful increase in progression-free survival and time to first subsequent th...
News Author: Sharon Worcester Publish date: June 12, 2017
CHICAGO – There may be a new standard of care on the horizon for patients with PC.
Video Author: Sharon Worcester Publish date: June 7, 2017
CHICAGO – There is a need for individualized therapy, which may result in shorter treatment durations and reduced toxicity.
Video Author: Sharon Worcester Publish date: June 7, 2017
CHICAGO – The risk of an invasive disease-free survival event was reduced 19% when pertuzumab was added to adjuvant chemotherapy and trastuzumab.
Video Author: Sharon Worcester Publish date: June 5, 2017
CHICAGO – With improved survival and a host of other benefits, why wouldn’t you encourage your patients to self-report?
News Author: Sharon Worcester Publish date: June 5, 2017
NEW YORK – Consider CLL patients with NOTCH1 gene mutation for chemotherapy “without type1 CD20 antibodies or a treatment with novel compounds.”
Video Author: Sharon Worcester Publish date: June 4, 2017
CHICAGO – Adding abiraterone acetate plus prednisone to androgen deprivation therapy in hormone-naive prostate cancer patients significantly improv...
News Author: Sharon Worcester Publish date: May 31, 2017
Committee members expressed concern about the broadness of the indication proposed by the drug’s maker.
News Author: Sharon Worcester Publish date: May 30, 2017
NEW YORK – Could a three-course regimen for CLL have a positive affect on treatment?
News Author: Sharon Worcester Publish date: May 26, 2017
How could a new epoetin alfa biosimilar change care and what are some concerns?